BR112017022281A2 - métodos para tratar câncer - Google Patents

métodos para tratar câncer

Info

Publication number
BR112017022281A2
BR112017022281A2 BR112017022281A BR112017022281A BR112017022281A2 BR 112017022281 A2 BR112017022281 A2 BR 112017022281A2 BR 112017022281 A BR112017022281 A BR 112017022281A BR 112017022281 A BR112017022281 A BR 112017022281A BR 112017022281 A2 BR112017022281 A2 BR 112017022281A2
Authority
BR
Brazil
Prior art keywords
methods
treat cancer
compound
kits
administration
Prior art date
Application number
BR112017022281A
Other languages
English (en)
Portuguese (pt)
Inventor
J Li Chiang
J Hitron Matthew
Li Wei
Li Youzhi
Gao Yuan
Original Assignee
Boston Biomedical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Biomedical Inc filed Critical Boston Biomedical Inc
Publication of BR112017022281A2 publication Critical patent/BR112017022281A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112017022281A 2015-04-17 2016-04-18 métodos para tratar câncer BR112017022281A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562149349P 2015-04-17 2015-04-17
US201662280947P 2016-01-20 2016-01-20
PCT/US2016/028177 WO2016168856A1 (en) 2015-04-17 2016-04-18 Methods for treating cancer

Publications (1)

Publication Number Publication Date
BR112017022281A2 true BR112017022281A2 (pt) 2018-07-10

Family

ID=55854799

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017022281A BR112017022281A2 (pt) 2015-04-17 2016-04-18 métodos para tratar câncer

Country Status (16)

Country Link
US (1) US20180085341A1 (https=)
EP (1) EP3283069A1 (https=)
JP (1) JP2018511643A (https=)
KR (1) KR20180006918A (https=)
CN (1) CN107666906A (https=)
AU (1) AU2016247319A1 (https=)
BR (1) BR112017022281A2 (https=)
CA (1) CA2983010A1 (https=)
EA (1) EA201792287A1 (https=)
HK (1) HK1250944A1 (https=)
IL (1) IL255022A0 (https=)
MX (1) MX2017013360A (https=)
PH (1) PH12017501879A1 (https=)
SG (2) SG10201900564WA (https=)
TW (1) TW201713327A (https=)
WO (1) WO2016168856A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3050566B1 (en) 2007-09-10 2018-11-28 Boston Biomedical, Inc. A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors
EP2983790A2 (en) 2013-04-09 2016-02-17 Boston Biomedical, Inc. Methods for treating cancer
WO2017132049A1 (en) * 2016-01-20 2017-08-03 Boston Biomedical, Inc. Methods for treating cancer
JP7106563B2 (ja) 2016-11-29 2022-07-26 スミトモ ファーマ オンコロジー， インコーポレイテッド ナフトフラン誘導体、その調製、および使用方法
CA3062656A1 (en) 2017-05-17 2018-11-22 Boston Biomedical, Inc. Methods for treating cancer
CN111093660A (zh) * 2017-09-05 2020-05-01 Epizyme股份有限公司 用于治疗癌症的组合疗法
EP3865130A4 (en) * 2018-10-12 2022-07-20 1Globe Biomedical Co., Ltd. NEW COMBINATION SOLUTION FOR THE TREATMENT OF CHEMOTHERAPY-REFRACTORY CANCER
EP3705893A1 (en) * 2019-03-05 2020-09-09 Humanitas Mirasole S.p.A. Methods to assess the risk of being affected by prostate cancer
WO2020197505A1 (en) * 2019-03-27 2020-10-01 Singapore Health Services Pte Ltd Biomarker with therapeutic implications for peritoneal carcinomatosis

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3050566B1 (en) * 2007-09-10 2018-11-28 Boston Biomedical, Inc. A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors
EP2547205B1 (en) 2010-03-19 2024-03-20 1Globe Biomedical Co., Ltd. Novel methods for targeting cancer stem cells
RU2571661C2 (ru) 2010-03-19 2015-12-20 Бостон Байомедикал, Инк. Новые соединения и композиции для нацеливания на злокачественные стволовые клетки
US9150530B2 (en) 2011-03-04 2015-10-06 Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. Esters of 4, 9-dihydroxy-naphtho [2, 3-b] furans for disease therapies
US8977803B2 (en) 2011-11-21 2015-03-10 Western Digital Technologies, Inc. Disk drive data caching using a multi-tiered memory
WO2013166618A1 (en) * 2012-05-08 2013-11-14 Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. PRODRUGS OF 4,9-DIHYDROXY-NAPHTHO[2,3-b]FURANS FOR CIRCUMVENTING CANCER MULTIDRUG RESISTANCE
EP2983790A2 (en) 2013-04-09 2016-02-17 Boston Biomedical, Inc. Methods for treating cancer
WO2017132049A1 (en) * 2016-01-20 2017-08-03 Boston Biomedical, Inc. Methods for treating cancer

Also Published As

Publication number Publication date
US20180085341A1 (en) 2018-03-29
CA2983010A1 (en) 2016-10-20
KR20180006918A (ko) 2018-01-19
EP3283069A1 (en) 2018-02-21
PH12017501879A1 (en) 2018-03-05
IL255022A0 (en) 2017-12-31
AU2016247319A1 (en) 2017-11-02
SG11201708504XA (en) 2017-11-29
SG10201900564WA (en) 2019-02-27
MX2017013360A (es) 2018-08-01
WO2016168856A1 (en) 2016-10-20
TW201713327A (zh) 2017-04-16
HK1250944A1 (zh) 2019-01-18
CN107666906A (zh) 2018-02-06
JP2018511643A (ja) 2018-04-26
EA201792287A1 (ru) 2018-03-30

Similar Documents

Publication Publication Date Title
CO2019007863A2 (es) Derivados de benzooxazol como inmunomoduladores
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
BR112017022281A2 (pt) métodos para tratar câncer
JOP20190194A1 (ar) مركبات نيوكليوتيدات ثنائية حلقية لعلاج السرطان
CO2019000386A2 (es) Compuestos heterocíclicos como inmunomoduladores
MX2016002137A (es) Ciertas entidades quimicas, composiciones y metodos.
CO2017011484A2 (es) Inhibidores de bromodominio
EA201792205A1 (ru) Гетероциклические соединения как ингибиторы lsd1
DOP2017000078A (es) Indazoles sustituidos con bencilo como inhibidores de bub1.
MX2018005315A (es) Composiciones y metodos para el tratamiento del cancer.
EA201891910A1 (ru) Гетероарильные ингибиторы pad4
CL2016003261A1 (es) Formulación que comprende un profármaco de gemcitabina
CL2015001990A1 (es) Compuestos de pirrolopirimidina substituidos, composiciones de los mismos, y métodos de tratamiento con los mismos.
UY37017A (es) Inhibidores aza-bencimidazol de pad4
MX2018003301A (es) Inhibidores de pcna.
MX2016009590A (es) Composiciones de apilimod y métodos para usar las mismas.
MX2018010993A (es) Derivados de icariina e icaritina.
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
UY36204A (es) Derivados de insoindolina.
MX2017001352A (es) Derivados de pirrolidinona como inhibidores de metionina aminopeptidasa 2 (metap-2).
UY36286A (es) Tratamientos médicos basados en anamorelina
BR112017022269A2 (pt) métodos para tratar câncer
BR112017022296A2 (pt) métodos para tratar câncer
MX2019003311A (es) Metodos para tratamiento de cancer de ovario.
CR20190028A (es) Compuestos heterocíclicos como inmunomoduladores

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]